Please join Ocular Therapeutix™ for its 2026 Investor Day featuring presentations from Ocular’s senior leadership and roundtable discussions with prominent retinal disease Key Opinion Leaders (KOLs), followed by a live Q&A session. In-person attendees are invited to join Ocular’s leadership team for a networking reception to conclude the event.

The prominent retinal disease KOLs participating in Ocular’s Investor Day include:

• Dr. Arshad M. Khanani MD, MA, FASRS: Managing Partner, Director of Clinical Research and Director of Fellowship, Sierra Eye Associates; Clinical Professor, University of Nevada, Reno School of Medicine.
• Dr. Lejla Vajzovic, MD, FASRS: Professor of Ophthalmology at Duke University School of Medicine.
• Dr. Darius M. Moshfeghi, MD: Chief of the Retina Division at Byers Eye Institute of Stanford University School of Medicine.

Presentations from Company leadership and KOL discussions will focus on regulatory updates regarding the NDA submission plan for AXPAXLI in wet AMD; a review of the ongoing SOL-R and SOL-X trials in wet AMD; an update on the registrational program for AXPAXLI in diabetic retinopathy; and an overview of the planned commercialization strategy for AXPAXLI in wet AMD, if approved.